Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for large-scale genetic analysis, specifically its proprietary BeadArray technology. The company targets life sciences, pharmaceutical, agriculture, and food industries. Revenue to date is primarily derived from government grants and research funding, with initial commercial sales of custom oligonucleotides and SNP genotyping services commencing in 2001.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2001 |
Nine Months Ended Sep 30, 2001 |
Nine Months Ended Sep 30, 2000 |
|---|---|---|---|
| Revenue | $691,356 | $1,724,888 | $824,446 |
| Net Loss | $(5,784,894) | $(16,595,898) | $(13,990,049) |
| Loss Per Share (Basic/Diluted) | $(0.19) | $(0.56) | $(1.66) |
| Operating Cash Flow | N/A | $(10,585,586) | $(4,092,311) |
| Investing Cash Flow | N/A | $(102,484,305) | $1,106,928 |
| Financing Cash Flow | N/A | $711,514 | $103,404,111 |
| Cash & Equivalents (End of Period) | $3,743,359 | $3,743,359 | $121,582,842 |
| Total Investments & Restricted Cash | $96,750,440 | $96,750,440 | N/A |
| Total Assets | $127,544,885 | $127,544,885 | $132,792,679 |
| Deferred Revenue | $10,062,500 | $10,062,500 | $5,000,000 |
Debt & Liquidity: As of September 30, 2001, the company held approximately $100.5 million in cash, cash equivalents, and investments. Total debt obligations (equipment notes) were approximately $955,000 ($287k current, $668k long-term). The company has an accumulated deficit of $41.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue for the nine months ended September 30, 2001, increased to $1.7 million from $0.8 million in the prior year period. This growth is driven by the initiation of commercial oligonucleotide sales and SNP genotyping services, though government grants still accounted for 69% of revenue (down from 97% in 2000).
- Expense Increases: Research and Development (R&D) expenses rose significantly to $14.6 million for the nine-month period (from $9.7 million in 2000), driven by increased staffing and supplies to support commercialization. Selling, General, and Administrative (SG&A) expenses increased to $3.7 million (from $2.7 million) due to public company costs and staffing.
- Cash Position: Cash and cash equivalents decreased from $116.1 million at year-end 2000 to $3.7 million at September 30, 2001. This reduction was primarily due to a net cash outflow of $102.5 million in investing activities, largely from purchasing investment securities and property/equipment for a new facility.
- Deferred Revenue: Deferred revenue doubled to $10.1 million from $5.0 million, reflecting advance payments from strategic partners.
Outlook, Risks, and Management Commentary
- Commercialization Timeline: The company expects to commercialize its first products under its strategic partnership with Applied Biosystems in mid-2002. A delay was announced earlier in 2001 regarding this product introduction.
- Capital Requirements: Management expects current resources to fund operations for at least the next 24 months. However, the company anticipates continued net losses and negative cash flow as it scales R&D and manufacturing. Additional funding may be required sooner if commercialization is delayed.
- Facility Expansion: The company is constructing a new facility and expects to assume a $26 million, 10-year mortgage at a fixed rate of 8.36% upon closing in January 2002. This will significantly increase future interest expenses.
- Key Risks:
- Profitability: No commercially available microarray products exist yet; success depends on market acceptance of unproven technology.
- Partnership Dependency: Commercial success relies heavily on the Applied Biosystems partnership for instrument development and marketing.
- Manufacturing: Limited manufacturing experience and reliance on single-source suppliers for critical components (e.g., fiber optic bundles).
- Intellectual Property: Risks regarding patent protection and potential litigation in a competitive market.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $100.5 million liquid asset base against the projected $26 million mortgage assumption and ongoing operating losses.
- Partnership Status: Confirm the status of the Applied Biosystems partnership and the timeline for the mid-2002 product launch.
- Revenue Mix: Monitor the transition from grant-dependent revenue to commercial product/service revenue to assess sustainability.
- Facility Costs: Track the closing of the new facility purchase and the impact of the new $26 million debt on future interest expenses.
- Manufacturing Supply Chain: Assess the risk associated with single-source suppliers for critical product components.